ArticleBMJ open2025

Cost-effectiveness analysis of aducanumab versus placebo for patients with mild cognitive impairment and mild Alzheimer's disease.

Xiaomo Xiong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.